AtriCure Inc

AtriCure, Inc. is a corporation based in Mason, Ohio, with a workforce of 1,008 employees. The company generates an annual revenue of $1 billion. AtriCure, Inc. focuses on developing innovative technologies for the treatment of Afib and related conditions. AtriCure offers a range of medical devices and therapies, including the Isolator® Synergy™ Ablation System, the AtriClip® Left Atrial Appendage Exclusion System, and the Hybrid AF™ Therapy. These products are used by electrophysiologists and cardiothoracic surgeons worldwide to treat Afib and reduce complications associated with the condition. AtriCure's cryoICE cryoSPHERE® probe is also used for temporary ablation of peripheral nerves, providing pain relief during cardiac and thoracic procedures. AtriCure's Isolator® Synergy™ Ablation System holds a significant distinction as the first medical device to receive FDA approval for the treatment of persistent Afib. Furthermore, AtriCure's AtriClip® Left Atrial Appendage Exclusion System products are recognized as the most widely sold LAA management devices globally. For additional information about AtriCure's products and services, visit their website at atricure.com or follow them on Twitter @AtriCure.